receptor antagonist. Exhibits approximately six-fold selectivity for OX2
receptors. Decreases activity and increases sleep time in mice during the active phase, without affecting REM/NREM balance. Orally bioavailable. Brain penetrant.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
Betschart et al.
Distinct effects of IPSU and suvorexant on mouse sleep architecture.
Hoyer et al.